TV
Travere Therapeutics, Inc.
TVTX · NASDAQ
$62.76 -3.28% (-$2.13)
1M -3.77%
Market Cap $5.84B
P/E Ratio -
Div. Yield -
ROE 55.79%
Piotroski F-Score Moderate
5/9Valuation
0 /100
Expensive P/S 9.87x
P/B 238.00x
P/FCF 113.29x
Growth
100 /100
Growing Book val. growth 38.90%
Rev. growth 64.89%
FCF growth N/A
Profitability
38 /100
Moderate Net margin 7.35%
Op. margin 6.84%
FCF margin 8.71%
Quality
9 /100
Poor ROE 55.79%
ROA 5.44%
Asset turnover 0.74x
Debt
15 /100
High Current ratio 4.05x
Int. coverage -6.07x
Net debt/EBITDA 323.30x
Stability
23 /100
Unstable Rev. volatility 39.40%
EPS volatility 143.54%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about TVTX
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Eric Dube
Employees
497
Headquarters
San Diego
Upcoming events
29 OCT
Earnings
Upcoming earnings report